Clinical Trials | December 30, 2025
Biohaven reports Phase 2 depression trial results
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
Subscribe To Our Newsletter & Stay Updated
